← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodystaleEli LillyPhase 2

Cetuximab Sarotalocan Sodium (Cetuximab Sarotalocan Sodium)

Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleImmunityBio, Inc.Phase 3

atezolizumab (Tecentriq, Cisplatin/carboplatin and pemetrexed plus atezolizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleImmunityBio, Inc.Phase 3

pembrolizumab (Keytruda, Cisplatin/carboplatin and pemetrexed plus pembrolizumab.)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleIdris BahceApproved

durvalumab (Imfinzi, Consolidation durvalumab)

Non-small Cell Lung Cancer Stage III · Non-small Cell Lung Cancer Stage III

#Non-smallCellLungCancerStageIII#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleUniversity of Texas Southwester…Phase 2

durvalumab (Imfinzi, Consolidative Durvalumab)

Non Small Cell Lung Cancer; Lung Cancer Stage III · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleDong-A ST Co., Ltd.Phase 2

pembrolizumab (Keytruda, DA-4505 + Pembrolizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab dose escalation)

Allosensitization; Kidney Transplant Rejection · Allosensitization

#Allosensitization#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab full dose)

Allosensitization; Kidney Transplant Rejection · Allosensitization

#Allosensitization#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab plus chemotherapy according to the national treatment program)

T-Lymphocytic Leukemia, Acute · T-Lymphocytic Leukemia, Acute

#T-LymphocyticLeukemiaAcute#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#항체#면역항체+2
효능 ORR 0%임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Docetaxel/Carboplatin/Bevacizumab/Erlotinib (Docetaxel/Carboplatin/Bevacizumab/Erlotinib)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGilead SciencesPhase 2

DOM (Domvanalimab, Domvanalimab (DOM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#항체#면역항체+4
효능 ORR 88%임상시험 1상태 RECRUITING
AntibodystaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 2

for the first 8, 21-day, cycles (Durvalumab, Durvalumab (for the first 8, 21-day, cycles))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

starting from cycle 9 (Durvalumab, Durvalumab (starting from cycle 9))

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation · Locally Advanced, Unresectable or Metast

#LocallyAdvancedUnresectableorMet#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Gem/Cis)

Biliary Tract Neoplasms; Gallbladder Cancer · Biliary Tract Neoplasms

#BiliaryTractNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Durvalumab + Monalizumab)

Stage III Non-small Cell Lung Cancer; Unresectable · Stage III Non-small Cell Lung Cancer

#StageIIINon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 23.9%임상시험 1상태 ACTIVE

7 / 15 페이지

← 이전다음 →